Companies: 10,795·Total market cap: $144.5T
Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc.

CYCCNASDAQHealthcare
$6.37
$-0.41(-5.98%)
Market Cap$10608329
P/E Ratio
52W High$597.59973
52W Low$3.0801
Overview

Cyclacel Pharmaceuticals, Inc. (CYCC) Revenue

Annual & quarterly revenue history · segment & region breakdown

CYCC · revenue · updated Jun 9, 2026

Core revenue metrics

Cyclacel Pharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from — in FY.

TTM revenue
$0.00B
4-quarter sum · USD
YoY growth
+0.00%
vs FY
Price / sales
14.19×
mktCap ÷ TTM rev
Revenue per day
$0M
Est. TTM ÷ 365
Revenue / employee
$62K
12 employees
FY
FY
5Y CAGR
Fiscal year end
Dec 31
Currency
USD · GAAP
Filing
10-K / 10-Q
Source: FMP · Cyclacel Pharmaceuticals, Inc. SEC filings · GAAPUpdated: 2026-06-09

Revenue trend

· Annual
YoY revenue growth %
revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year endRevenueChangeGrowth
CYCC revenue by year · CYCC revenue history · CYCC annual revenue data

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income Cyclacel Pharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

Cyclacel Pharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from Cyclacel Pharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Frequently asked questions

CYCC revenue · 4 questions

CYCC's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from — in FY.

CYCC revenueCYCC annual revenuewhat is CYCC revenueCYCC TTM revenue

Source: FMP · Cyclacel Pharmaceuticals, Inc. SEC filings · GAAP · Cyclacel Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026